Email this article Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy
- Authors: - -
- Issue: Vol 8, No 1 (2006)
- Pages: 71-73
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26637
- ID: 26637
Cite item
Full Text
Abstract
Несмотря на доступность целого ряда новых противоопухолевых препаратов, антрациклины сохраняют свое важнейшее место в терапии больных МРМЖ. Однако применение доксорубицина ограничено его токсическими эффектами и, прежде всего развитием кумулятивной кардиотоксичности. Новый противоопухолевый препарат «Келикс» - пегилированный липосомальный доксорубицин - убедительно продемонстрировал эффективность в многоцентровых рандомизированных исследованиях III фазы у больных МРМЖ, как в 1-й линии, так и при резистентности к традиционным антрациклинам и таксанам.
Full Text
##article.viewOnOriginalSite##References
- Cameron R.B. Malignancies of the Breast. Chap. 53 in A Lange Clinical Manual - Practical Oncology 1st Edition. Norwalk: Appleton & Lange, 1994.
- Skipper H.E. Criteria Associated with Destruction of Leukemia and Solid Tumor Cells in Animals. Cancer Res 1967; 27:2636-45.
- Frei E, Teicher B.A, Holden S.A, Cathcart K.N, Wang Y.Y. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
- Norton L, Hortobagyi G.N, Shpall E.J. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335-340.
- Papahadjopoulous D, Allen T.N, Gabizon A., et al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
- Data on File SEQUUS Nonclinical Toxicology Reports: LTI-30-93-24 (rats), LTI-30-94-14 (dogs), LTI-30-94-28 (rabbit).
- Martin F.J, Gabizon A, Human Pharmacokinetics of Stealthв Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
- North D, et al. Pharmacokinetics (PK), Tumour Localization (TL) and Safety of CAELYX (Liposomal Doxorubicin ) in AIDS Patients with Kaposi’s Sarcoma (AIDS-KS). Proceedings from the American Society of Oncology, 1993; 12:51.
- Vaage J, Mayhew E, Lasic D, et al. Therapy of Primary and Metastatic Mouse Mammary Carcinomas with Doxorubicin Encapsulated in Long Circulating Liposomes. Int. J. Cancer, 1992; 51:942-8.
- Ozols R.B, et al. Chemotherapy for Murine Ovarian Cancer: A Rationale for IP Therapy with Adriamycin. Cancer Treat Rep., 1979; 63:269-74.
- Chavdury P.M, Roninson I.B. Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J Natl Cancer Institute, 1993; 85:632-9.
- Ouclard S, et al. Sensitization of Multidrug-Resistant Colon Cancer Cells to Doxorubicin Encapsulated in Liposomes. Cancer Chemother Pharmacol, 1991; 28(4):259-65.
- Thierry A.R, et al. Effect of Liposomes on P Glycoprotein Function in Multidrug-Resistant Cells. Biochem-Biophys Res Commun, 1992; 187:1098-105.
- Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777-85.
- Berry G, Billingham M, Torti F, et al. Reduced Cardiotoxicity in AIDS Kaposi’s Sarcoma Patients Treated with Pegylated Liposomal Doxorubicin (CAELYXв) as Compared to Conventional Doxorubicin. In preparation.
- Muggia F., Hainsworth J., Jeffers S., et al. Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation. J. Clin. Oncol. Vol. 15, No3 (March) 1997: p. 987-93
- Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
- O’Brien N. Wigler, M. Inbar et al. , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil)vs conventional doxorubicinfor first - line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
